Literature DB >> 8774645

Peripheral infusion ports for central venous access in patients with gynecologic malignancies.

M J Cunningham1, M B Collins, D C Kredentser, J H Malfetano.   

Abstract

During treatment for gynecologic malignancies, many patients require frequent or prolonged intravenous access. Implantable permanent venous access devices are useful in assuring adequate access and improving quality of life. A new technique for central venous access by peripheral placement of a subcutaneous infusion port was evaluated in 18 women undergoing treatment for gynecologic malignancies. Patients were followed prospectively with a mean follow-up of 105 days. Six catheters required removal because of complications, including 1 patient with a catheter site infection and 5 patients (26%) with catheter-related thrombosis. Although the rate of immediate insertion-related complications was low, the incidence of deep venous thrombosis was markedly increased over that reported with other central venous access devices.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8774645     DOI: 10.1006/gyno.1996.0061

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

1.  Local thrombolytic therapy in cancer patients with central venous catheter occlusion in urgent need of antiblastic treatment: a single institution experience.

Authors:  Alberto Agazzi; Daniele Laszlo; Franco Orsi; Roberto Biffi; Giovanni Martinelli
Journal:  J Thromb Thrombolysis       Date:  2003-04       Impact factor: 2.300

Review 2.  Systematic review: malfunction of totally implantable venous access devices in cancer patients.

Authors:  Godelieve Alice Goossens; Marguerite Stas; Martine Jérôme; Philip Moons
Journal:  Support Care Cancer       Date:  2011-05-10       Impact factor: 3.603

3.  Long-term outcomes of peripheral arm ports implanted in patients with colorectal cancer.

Authors:  Junichiro Kawamura; Satoshi Nagayama; Akinari Nomura; Atsushi Itami; Hiroshi Okabe; Seiji Sato; Go Watanabe; Yoshiharu Sakai
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.